What do systematic reviews say?

Flutamide 250 mg once to b.i.d. vs metformin 1275 mg to 1700 mg per day

The review found no eligible studies for this question.

• Interventions for hirsutism (excluding laser and photoepilation therapy alone) 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Finasteride 5 mg vs flutamide 250 mg once to b.i.d.

The review found no eligible studies for this question.

• Interventions for hirsutism (excluding laser and photoepilation therapy alone) 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Flutamide 250 mg b.i.d. vs placebo

The review found no eligible studies for this question.

• Interventions for hirsutism (excluding laser and photoepilation therapy alone) 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Combination hearing aid vs hearing aid

The review found no eligible studies for this question.

• Sound therapy (using amplification devices and/or sound generators) for tinnitus 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Hearing aid vs sound generator

The review found no eligible studies for this question.

• Sound therapy (using amplification devices and/or sound generators) for tinnitus 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Ruxolitinib vs best available therapy

• Janus kinase‐1 and Janus kinase‐2 inhibitors for treating myelofibrosis 2015 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 96 participants
  Low

Intervention not reported

• Radioiodine therapy versus antithyroid medications for Graves' disease 2016 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 425 participants
  GRADE not reported

Next‐generation ALK inhibitor vs crizotinib

It is very uncertain whether next‐generation ALK inhibitor changes health‐related quality of life: time to deterioration in composite… compared with crizotinib (very low certainty).

• Targeted therapy for advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer 2022 · Cochrane Headline outcomes only
  HR 1.1 [0.72, 1.68]
  1 study · 303 participants
  Very low

Intervention not reported

• Sulphonylurea monotherapy for patients with type 2 diabetes mellitus 2013 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 35 participants
  Very low

SCS treatment for 7 or fewer days vs SCS treatment

• Different durations of corticosteroid therapy for exacerbations of chronic obstructive pulmonary disease 2018 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 271 participants
  Moderate